Oncology - Hematology

Host: Jennifer Caudle, DO Guest: Joyce O'Shaughnessy, MD The results from the phase III EMERALD trial led to the approval of ORSERDU (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy. But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.

Guest: Adam Narloch Guest: Michelle Hermiston, MD, PhD Adam Narloch speaks with Dr Michelle Hermiston to discuss the history of hemophagocytic lymphohistiocytosis (HLH) and advances in understanding this rare disease. Dr Hermiston is a pediatric hematologist-oncologist, a bone marrow transplant specialist, and the Director of the Pediatric Immunotherapy Program at UCSF Benioff Children’s Hospital. Join us as we start our journey into the world of HLH! © 2024 Sobi, Inc. All Rights Reserved. NP-34329 04/24

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jamie Koprivnikar, MD Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health. REBLOZYL is a trademark of Celgene Corporation, a Bristol Myers Squibb company. REBLOZYL is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates. © 2024 Bristol-Myers Squibb Company 2007-US-2300376 03/24

Host: Sana Raoof, MD, PhD Guest: Candace T. Westgate, DO, MPH, FACOG Guest: Mylynda Massart, MD, PhD The last five years have seen exciting progress with liquid biopsy tests, with one of them being a screening tool for multi-cancer early detection that looks for methylation patterns that can detect more cancers earlier, even before symptoms appear. Learn how you can incorporate this screening tool into clinical practice with Drs. Sana Raoof, Candace Westgate, and Mylynda Massart. Dr. Raoof is a physician scientist at Memorial Sloan Kettering Cancer Center, Dr. Westgate is the Medical Director of the AHEAD Program and Chief of Staff at Adventist Health Saint Helena in Northern California, and Dr. Massart is the Founder and Director of the UPMC’s Primary Care Precision Medicine Center. References: Cancers (Basel).Ann Oncol.

Host: Jennifer Caudle, DO Guest: Sana Raoof, MD, PhD There’s a multi-cancer early detection test available that uses a targeted methylation, next-generation sequencing-based assay to detect and analyze cell-free DNA in the bloodstream, deploy machine learning to detect a cancer signal, and predict the likely origin of the signal. Explore the science behind this advancement that provides the highest specificity of any cancer screening tool with Dr. Jennifer Caudle and Dr. Sana Raoof, physician scientist at Memorial Sloan Kettering Cancer Center. References: Cancers (Basel).Ann Oncol.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jerome Goldschmidt, MD Despite the potential benefits of biosimilars, such as decreased costs for patients, healthcare systems, and payers, their uptake in U.S. clinical practice has lagged behind that of the E.U.That’s why Dr. Jerome Goldschmidt joins Dr. Charles Turck to address common misconceptions surrounding biosimilars and examine key points in their development, manufacturing, and approval process. Dr. Goldschmidt is a medical oncology specialist practicing at Blue Ridge Cancer Care, and he’s also affiliated with the U.S. Oncology Network in Blacksburg, Virginia. References: 1. IQVIA. Biosimilars in the United States 2023–2027: Competition, Savings, and Sustainability. 2023. Accessed June 20, 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2023-2027 2. Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. doi:10.1016/j.semarthrit.2021.11.009 ©2023 Amgen Inc. All rights reserved. USA-CBU-81658 8/23

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Gil Melmed, MD, MS The inflammation biosimilar development process uses a stepwise approach with increasing certainty to generate the totality of evidence, which demonstrates the safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed. Dive further into the role of totality of evidence in the inflammation biosimilar development and approval process with Dr. Gil Melmed, Director of Inflammatory Bowel Disease Clinical Research at the Cedars-Sinai and Professor of Medicine at Cedars-Sinai and at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Melmed was compensated for participating in this program. References: https://www.fda.gov/media/135612/download https://www.fda.gov/media/82647/download ©2023 Amgen Inc. All rights reserved. USA-CBU-81605 5/23